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Abstract
The tetracycline antibiotics are widely used in biomedical research as mediators of inducible gene expression systems.
Despite many known effects of tetracyclines on mammalian cells–including inhibition of the mitochondrial ribosome–there
have been few reports on potential off-target effects at concentrations commonly used in inducible systems. Here, we
report that in human cell lines, commonly used concentrations of doxycycline change gene expression patterns and
concomitantly shift metabolism towards a more glycolytic phenotype, evidenced by increased lactate secretion and
reduced oxygen consumption. We also show that these concentrations are sufficient to slow proliferation. These findings
suggest that researchers using doxycycline in inducible expression systems should design appropriate controls to account
for potential confounding effects of the drug on cellular metabolism.
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Introduction
The tetracycline family is a class of broad-spectrum antibiotics
that have been used clinically since the mid-twentieth century.
Since then, they have found application beyond their anti-
microbial activity in both the clinic and biomedical research [1–3].
They are widely used in the latter context as mediators of
inducible gene expression systems, but often with little discussion
of or control for potential off-target effects they may have on
mammalian cells. Because the tetracyclines have been shown to
inhibit matrix metalloproteinases, retard proliferation, induce
apoptosis, and impair mitochondrial function in various experi-
mental settings, we were interested to determine whether these
drugs can alter cellular metabolism at concentrations commonly
used in inducible systems [4–12].
The canonical prokaryotic target of the tetracyclines is the
bacterial ribosome, the inhibition of which blocks bacterial protein
synthesis [1]. But there is significant evidence that tetracyclines can
impair mitochondrial function in eukaryotic cells by inhibiting
translation at the mitochondrial ribosome, an observation that has
been explained by the origin of these organelles as endosymbiotic
bacteria [8,12–15]. Despite a reportedly weak interaction between
the antibiotics and the mitochondrial ribosome, at high concen-
trations they have been shown to impair synthesis of proteins
encoded in the mitochondrial genome–many of which are
involved in oxidative metabolism–and promote a shift towards
glycolysis [4].
In this study, we expanded upon these findings to determine
potential confounding effects of the tetracyclines–particularly
doxycycline (Dox), the predominantly used compound–at concen-
trations commonly employed in inducible gene expression systems:
100 ng/mL - 5 mg/mL. We found that these concentrations of
drug can significantly alter the metabolic profile of the cell, as well
as reduce the proliferative rate, though the effect size depends
upon the particular cell line used. These data strongly suggest that
researchers using Dox-inducible systems should carefully optimize
experiments to minimize potentially confounding effects of the
drug, and design additional controls as needed.
Results
Doxycycline Induces Metabolic Gene Expression Changes
in Human Cells
To look in an unbiased way at the effects of Dox on cells in
culture, we performed gene expression analysis on MCF12A cells–
an untransformed breast epithelial line–treated with the drug at
1 mg/mL or with a vehicle control. Metabolic pathway enrich-
ment analysis (using Gene Set Enrichment Analysis (GSEA))
revealed several pathways, including oxidative phosphorylation
and glycolysis, to be significantly enriched in the Dox-treated cells
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(Figure 1A; for enrichment plots, see Figure S1). Many of the
constituent genes in these pathways show a robust change in
expression in response to treatment (Figure 1B; for annotated gene
sets, see Figure S2), including key enzymes in glycolysis and its
major carbon shunts (Figure 1C). These results demonstrate that
Dox, at a concentration commonly used in inducible systems, can
alter the metabolic gene expression profile of cells.
Doxycycline Increases Glycolytic Metabolism in Multiple
Human Cell Lines
Because treatment with Dox alters expression of genes involved
in glycolysis and oxidative phosphorylation, we tested whether
Dox treatment causes corresponding functional metabolic changes
in MCF12A cells. As shown in Figure 2, glucose consumption
(Figure 2A) and lactate production rates (Figure 2B) are elevated in
MCF12A cells after 96 hours of treatment with 1 mg/mL Dox.
The Dox analogs tetracycline (Tet) and minocycline (Mino) were
also tested at 1 mg/mL. Both drugs induced increased lactate
production rates (Figure 2B), and Mino concomitantly caused
increased glucose uptake–though this latter phenotype is not
observed with Tet (Figure 2A). Significant changes were also
observed at 100 ng/mL with Mino and Tet, but the effect size is
considerably smaller.
To determine whether the effect of Dox on cellular metabolism
is dose-dependent, we measured lactate production rates
(Figures 2C and 2D) and oxygen consumption rates (Figures 2E
and 2F) of MCF12A and 293T cells over a range of Dox doses
commonly used experimentally (100 ng/mL–5 mg/mL). We
found that the amount of Dox used correlates with the shift
towards a glycolytic phenotype, as shown by increased lactate
production and decreased oxygen consumption. Higher doses of
Dox (10 mg/mL) lead to cytotoxic effects (data not shown). In this
range of concentrations, there appears to be a clear relationship
between the Dox dose and the magnitude shift towards glycolysis
Figure 1. Doxycycline alters the metabolic gene expression profile of MCF12A cells. Treatment of MCF12A cells with Dox at a
concentration of 1 mg/mL shows widespread changes in expression of metabolic genes. A) GSEA reveals the most significantly altered metabolic
pathways, ranked by normalized enrichment score (NES), in Dox treatment compared to vehicle. KEGG pathway entries are denoted in parentheses
where appropriate. Pathways without KEGG entries–All Metabolic Genes and Glycolysis-Gluconeogenesis & Pentose Phosphate–are artificial
combinations of other pathways with redundant genes collapsed. All Metabolic Pathways includes all non-redundant genes from every KEGG
pathway analyzed. B) This heat map highlights changes in the constituent genes of the oxidative phosphorylation and glycolysis/gluconeogenesis/
pentose phosphate pathways upon treatment. Annotated genes include those encoding regulatory enzymes in glycolysis (phosphofructokinase
(PFK), hexokinase (HK), pyruvate kinase (PK), shown in blue) and in gluconeogenesis (glucose-6-phosphatase (G6PC) and fructose-1,6-bisphosphatase
(FBP), shown in orange). (C) Altered expression of regulatory enzymes in glycolysis and its proximal carbon shunts are shown schematically, with red
indicating upregulation and green indicating downregulation.
doi:10.1371/journal.pone.0064561.g001
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and away from oxidative metabolism in MCF12A and 293T cells.
These results suggest that the tetracycline family of antibiotics can
promote glycolytic metabolism in human cell lines.
To assess whether the Dox-mediated metabolic changes are cell
type-specific or broadly generalizable to human cell lines, we
repeated the metabolic assays on 9 different human cell lines–both
transformed and untransformed–and observed enhanced glycoly-
sis in a majority of them (6/9, for both glucose consumption and
lactate production rates) (Figures 3A and 3B). There is consider-
able evidence suggesting that the tetracyclines interact with the
mitochondrial ribosome and inhibit translation of transcripts from
the mitochondrial genome. Accordingly, we measured basal
oxygen consumption rates in the cell line panel after 96 hours of
Dox treatment (Figure 3C) [14]. In all cell lines but 293T, oxygen
consumption was significantly impaired at 1 mg/mL; three lines
showed significant defects at 100 ng/mL. The magnitude of the
decrease varied among the cell lines, with H157 cells experiencing
a 70% reduction in oxygen consumption, despite having
unaffected glycolytic flux. To understand the temporality of this
phenotype, we measured oxygen consumption after treating
MCF12A cells with 1 mg/mL Dox for 24, 48, and 72 hours,
which revealed a significant reduction in the oxygen consumption
rate post 48 hours of treatment (Figure 3D). Together, these data
demonstrate that Dox concentrations commonly used in genetic
systems can substantially reprogram metabolism in human cell
lines, and that the phenotype can vary significantly among cell
lines.
Doxycycline Reduces Proliferation of Multiple Human Cell
Lines
Previous studies have shown that Dox can impair cell
proliferation in vitro [8]. Measuring cell number over a 96-hour
time course, we found that at 1 mg/mL–but not 100 ng/mL–
Dox treatment significantly reduces proliferation in most of the
cell lines in our panel (7/9); only one cell line, the LNCaP
prostate cancer line, experienced a proliferative defect at the
lower concentration. Here, we show both representative growth
curves for MCF12A and 293T cells (Figures 4A and 4B) and
normalized values for the entire panel (Figure 4C). Interestingly,
not all cell lines that experience substantial Dox-induced
metabolic shifts have simultaneously impaired proliferative
capacity–most clearly seen in MCF10A cells (Figures 3A–3C;
Figure 2. Tetracycline antibiotics affect glucose metabolism and oxygen consumption in a dose-dependent fashion. Effects of the
tetracyclines on glycolytic flux were determined by measuring changes in A) glucose consumption and B) lactate production rates of MCF12A cells
when treated with Dox, Mino, or Tet at 100 ng/mL or 1 mg/mL. A dose-response relationship was established between Dox and C) lactate production
rate in MCF12A cells, D) lactate production rate in 293T cells, E) oxygen consumption rate in MCF12A cells, and F) oxygen consumption rate in 293T
cells by treating with a range of drug concentrations. Error bars represent standard deviation from experimental triplicate measurements for all
assays, except for oxygen consumption dose-response in 293T cells, which was performed with 8 replicates. * denotes a p-value #0.05, ** a p-value
#0.01 from a two-tailed Student’s t-test.
doi:10.1371/journal.pone.0064561.g002
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Figure 4C)–suggesting potentially independent or decoupled
mechanisms of action.
To determine what might cause reduced proliferation, cell
cycle analysis was performed on MCF12A and 293T cells, both
of which experience metabolic and proliferative changes with
Dox treatment. Consistent with a previous report of tetracy-
cline-induced G1 arrest, propidium iodide (PI) staining showed
modest enrichment of cells in this phase of the cell cycle in
MCF12A cells (Figure 4D), but not in 293T cells (Figure 4E)
[5]. Because apoptosis has also been described in cells treated
with tetracyclines, Annexin V/PI co-staining was performed on
the same cells (Figures 4F and 4G) [5,8]. At the concentrations
used here, Dox significantly increases apoptotic cell death in
293T cells (Figure 4G), but not in MCF12A cells (Figure 4F).
Since the Dox-induced effects on cell cycle and apoptosis vary
between the cell lines tested, the mechanistic link between Dox
treatment and the observed modestly impaired proliferation
remains elusive.
Discussion
We show here that Dox, as well as other members of the
tetracycline family, can cause substantial changes in cellular
metabolism and impair proliferative capacity of human cell lines.
Importantly, these phenotypes are induced at concentrations
commonly used in inducible gene expression systems, which
indicates a strong possibility of confounding effects in these
experiments. Our findings are surprising given the presumed
inactivity of these drugs in eukaryotic cells, and particularly
relevant because metabolism and proliferation are fundamental
properties of the cell–inextricable from many other phenotypes.
While inducible gene expression systems are a powerful tool for
probing gene function, it is advisable that researchers carefully
optimize experiments in order to minimize the concentration of
Dox and the concomitant confounding phenotype. Additional
controls can also be designed so that the effects of the mediating
drug are disentangled from that of the gene of interest.
Because we did not investigate the mechanism of action, we
cannot fully explain how Dox causes the observed phenotypes. But
Figure 3. Doxycycline can alter both glycolytic and oxidative metabolism in a heterogeneous panel of human cell lines. Findings
were extended to a panel of human cell lines, which were treated with Dox for 96 hours at 100 ng/mL, 1 mg/mL, or with vehicle control and then
assayed for A) glucose consumption rate, B) lactate production rate, and C) basal oxygen consumption rate. D) To assess the temporality of this
phenotype, MCF12A cells were treated with Dox at 1 mg/mL at shorter time points–24, 48, and 72 hours–and oxygen consumption rate was
measured. Error bars represent standard deviation from experimental triplicate measurements in 3A and 3B; from 6 (100 ng/mL) or 7 (control, 1 mg/
mL) replicates in 3C; and from 5 replicates in 3D. Oxygen consumption measurements for 293T cells from Figure 2F were repurposed for 3C. * denotes
a p-value #0.05, ** a p-value #0.01 from a two-tailed Student’s t-test.
doi:10.1371/journal.pone.0064561.g003
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the evidence of interactions between the drug and the mitochon-
dria are compelling, and may contribute to our observations. Since
subunits of electron transport chain complexes are encoded in the
mitochondrial genome, a potential stoichiometric imbalance
caused by decreased translation of these genes could lead to
reduced capacity for oxidative metabolism and a compensatory
shift towards glycolysis [12,14,15]. While further investigation is
needed to refine our understanding of the effects of the drug on
human cells, these results highlight important confounding
phenotypes of Dox treatment and underscore the importance of
rigorous experimental design when using this compound in
inducible expression systems.
Materials and Methods
Cell Culture
U87 astrocytoma cells were a gift from Dr. Paul Mischel
(UCSD), lung cancer cell lines H157 and H1437 from Dr. Steven
Dubinett (UCLA), and LNCaP prostate cancer and HeLa cervical
cancer cell lines from Dr. Steven Bensinger (UCLA), and all other
cell lines from Dr. Frank McCormick (UCSF); all cell lines have
been well characterized [16–20]. MCF12A and MCF10A cells
were cultured in DMEM/F12 (1:1) containing 5% horse serum,
1% penicillin/streptomycin, 10 mg/mL insulin (Invitrogen),
0.5 mg/mL hydrocortisone (Sigma), 20 ng/mL EGF (Peprotech),
and 10 mg/mL cholera toxin (Sigma). HeLa and U87 cells were
cultured in DMEM containing 10% FBS and 1% penicillin/
streptomycin. H1437, H157, and LNCaP cells were cultured in
RPMI containing 10% FBS and 1% penicillin/streptomycin.
SUM159PT cells were cultured in F12 containing 5% FBS, 1%
penicllin/streptomycin, 5 mg/mL insulin (Invitrogen), 1 mg/mL
hydrocortisone (Sigma), and 0.1% gentamicin (Sigma). Doxycy-
cline, tetracycline, and minocycline (Sigma) were dissolved in
water. Media containing the drug was refreshed every 48 hours, as
appropriate.
Metabolic Pathway Enrichment Analysis
RNA extraction was performed using RNeasy (Qiagen)
according to manufacturer’s guidelines. Samples were analyzed
using the Affymetrix Genechip U133 Plus 2 array by the UCLA
Clinical Microarray Core Laboratory. Resulting data are available
Figure 4. Doxycycline reduces proliferation of multiple human cell lines. Cell numbers were measured over 96 hours of Dox treatment.
Shown here are representative growth curves for A) MCF12A and B) 293T cells, as well as C) the full panel of cell lines with cell counts after 96 hours
of treatment normalized to vehicle control. To interrogate the reason for the proliferation defect, PI-based cell cycle analysis was performed on D)
MCF12A and E) 293T cells, and Annexin V/PI viability analysis was performed on F) MCF12A and G) 293T cells. Both proliferation and flow cytometry-
based assays were performed in triplicate, with error bars representing standard deviation. * denotes a p-value#0.05, ** a p-value#0.01 from a two-
tailed Student’s t-test.
doi:10.1371/journal.pone.0064561.g004
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through NCBI’s Gene Expression Omnibus (GEO Series acces-
sion number GSE45029). To identify metabolic pathways
associated with Dox treatment, we used the GSEA algorithm
and metabolic pathway annotation defined by the Kyoto
Encyclopedia of Genes and Genomes (KEGG) (release #58).
We collapsed gene expression probes based on enzyme activity
(Enzyme Commission [EC] numbers) rather than on gene identity
to avoid unequal representation of equivalent enzymatic function
within pathways, thus emphasizing potential flux through the
network. The metric used for gene ranking was the signal to noise
ratio (SNR) between the Dox treatment and control. The
probesets were collapsed by average SNR for GSEA, and by
maximum absolute SNR for each enzyme in the heat maps.
Probeset annotation was based on UniGene build #230 and
UniGene identifiers were mapped to each EC using the gene
names provided by KEGG.
Media Metabolite Measurement
Media was collected from culture plates and analyzed for
glucose and lactate concentrations using the Bioanalyzer 4 (Nova
Biomedical). Cells were treated with Dox or vehicle control for 96
hours. Fresh media was added to plates between 20 and 24 hours
before sample collection. Values were normalized to both cell
number and time interval. Some statistical variability was observed
among experiments, particularly with respect to glucose, because
the effect size measured at these concentrations of Dox is small
compared to the error of the assay. Lactate is a more consistently
sensitive readout of glycolytic activity.
Oxygen Consumption Measurement
Basal oxygen consumption rates were measured using the XF24
Extracellular Flux Analyzer (Seahorse Bioscience). Cells were
treated with Dox or vehicle control for 96 hours, unless otherwise
indicated. 18 hours prior to assay, cells were seeded at 50,000–
80,000 cells per well (optimized for each cell line) in 24-well
proprietary assay plates with between 3 and 8 replicates per
treatment group. Oxygen consumption values were normalized to
total protein using BCA Protein Assay Kit (Pierce). Because plating
density around the oxygen sensors affects readings, there is
considerable well-to-well variability. Because cell morphology can
alter the distribution of cells in the well, different cell lines are
measured with varying sensitivity.
Proliferation Assay
Cells were seeded in 6 well plates at 50,000 cells per well and
treated with Dox (100 ng/mL, 1 mg/mL, or vehicle control). Cells
were counted 24, 72, and 96 hours after plating using a particle
counter (Beckman Coulter).
Cell Cycle Analysis
Cell cycle analysis was performed using propidium iodide (PI)
staining. In brief, cells were trypsinized and resuspended in
hypotonic DNA staining buffer (3.5 mM sodium citrate, 0.1 g/L
propidium iodide, 0.3% Triton X-100, 20 mg/L Ribonuclease A)
at a concentration of 106 cells/mL and incubated for 20 minutes at
room temperature in the dark. Analysis was performed using the
BD FACSDiva software on an LSR II flow cytometer (BD
Biosciences). PI fluorescence was recorded in the PE channel. For
cell cycle analysis, flow cytometry data was imported and analyzed
using the ModFit LT software.
Viability Analysis
Cell viability was measured using the FITC Annexin V
Apoptosis Detection Kit II (BD Pharmingen) according to the
manufacturer’s protocol. Cells were incubated with Annexin V
and PI for 15 min and then analyzed by flow cytometry as
previously described. Annexin V fluorescence was recorded on the
FITC channel and PI on the PE channel. Data was analyzed using
FlowJo. Cells in early apoptosis were indicated by Annexin V
positive, PI negative staining (lower right quadrant) while cells in
late apoptosis were marked by Annexin V/PI double positive
staining (upper right quadrant).
Supporting Information
Figure S1 Metabolic gene sets are enriched upon treatment with
Dox. Enrichment plots for the top ranked KEGG-defined
pathways in MCF12A cells treated with Dox at 1 mg/mL,
compared to vehicle control.
(TIF)
Figure S2 Dox treatment alters expression of genes
involved in major central carbon metabolism pathways.
Heat maps highlight changes in expression of genes in A) the
Glycolysis-Gluconeogenesis & Pentose Phosphate Pathway (artifi-
cial combination of KEGG pathways) and in B) KEGG-defined
Oxidative Phosphorylation after Dox treatment at 1 mg/mL in
MCF12A cells, compared to vehicle control. Entries are ranked by
SNR and are collapsed by enzyme function; the constituent gene
with the maximum absolute SNR is shown in the heat map.
Regulated enzymes in glycolysis are shown in blue and those in
gluconeogenesis are shown in orange.
(PDF)
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